Opioid Induced Constipation Treatment Market to Touch US$4.8 bn by 2023, Mu-opioid Receptor Antagonist to be Fastest-growing Segment: Transparency Market Research

Apr 06, 2016, 08:30 ET from Transparency Market Research

ALBANY, New York, April 6, 2016 /PRNewswire/ --

Transparency Market Research has published a new market report titled, "Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023". According to the report, the global opioid induced constipation treatment market was valued at US$0.4 bn in 2014 and is anticipated to expand at a CAGR of 31.2% from 2015 to 2023 to reach US$4.8 bn by 2023.

Avail a Sample Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries. However, mu-opioid receptor antagonist was the fastest growing segment due to recent launch of the new drug Moventik and presence of pipeline drugs (naldemedine and other early stage drugs). Mu-opioid receptor antagonist drugs target the root cause of constipation by acting on specific peripheral opioid receptors, which revert the opioid action without affecting opioids analgesic action. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. However, mu-opioid receptor antagonist class consists of Moventik (AstraZeneca), Relistor (Valeant Pharmaceuticals, Inc.), and Naloxone. Additionally, naldemedine is in the late stage clinical trial. The drug is investigational, oral, mu-opioid receptor antagonist and is expected to launch in mid-2016. In August 2015, Shionogi's naldemedine met primary and secondary endpoints in phase III clinical trial (COMPOSE II) to treat opioid induced constipation.

Linaclotide is another potential drug, which is currently in phase II clinical trial. Phase I clinical trial (KODIAK16) is underway to assess the efficacy and safety of naloxegol in the treatment of opioid induced constipation in pediatric patients. The trial is expected to be completed in November 2017. Hence, launch of pipeline drugs during the forecast period is expected to boost the growth the PAMORA segment. The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol, and polyethylene glycol). Major players in this segment are Boehringer Ingelheim GmbH and C.B. Fleet Company, Inc. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. However, low cost of therapy, high awareness, and easy access to medicines accounted significant share of the opioid induced constipation treatment market. For instance, monthly cost of standard laxative therapy ranges from US$ 6 to US$ 80. However, monthly cost of Amitiza ranges from US$ 300 to US$ 400 and from US$ 600 to US$ 1000 for Relistor.

Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.

Browse Research Report with TOC & Free Analysis: http://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html

Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. The solid dosage form segment accounted for the largest share of the market in 2014. The segment is expected to maintain its leadership position during the forecast period. This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. The semi-solid and liquid dosage form segments accounted for small shares of the market.

The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period. For instance, in March 2015, AstraZeneca and Daiichi Sankyo signed a co-commercialization agreement for Moventik in the U.S. In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Hence, strategic agreements between companies are expected to drive the opioid induced constipation treatment market during the forecast period from 2015 to 2023.  

Browse Regional PR: http://www.europlat.org/global-opioid-induced-constipation-treatment-market.htm

The Global Opioid Induced Constipation Treatment Market is segmented as follows:  

  • Global Opioid induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013-2023 (US$ Mn) 
    • Solid
    • Semisolid
    • Liquid
  • Global Opioid induced Constipation Treatment Market Revenue, by Drug Class, 2013-2023 (US$ Mn) 
    • Mu-opioid receptor antagonist
    • Chloride channel activator
    • Others
  • Global Opioid induced Constipation Treatment Market Revenue, by Pipeline, 2013-2023 (US$ Mn) 
    • Late Stage (Phase III) candidates (Forecast from the year of Approval till 2023) (US$ Mn)
      • Naldemedine
      • Others
    • Early Stage (Phase II and Phase I) candidates (Tabular Representation)
      • Axelopran
      • Others
  • Global Opioid induced Constipation Treatment Market Revenue, By Geography, 2013-2023 (US$ Mn) 
    • Overview
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Rest of the World

Other Reports by TMR: 

  • Active Pharmaceutical Ingredient Market:  

http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html

  • Nanotechnology Drug Delivery Market:  

http://www.transparencymarketresearch.com/nanotechnology-drug-delivery.html

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Contact:
Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/


SOURCE Transparency Market Research